Gene: GRAMD2B

65983
GRAMD3|NS3TP2
GRAM domain containing 2B
protein-coding
5q23.2
Ensembl:ENSG00000155324 Vega:OTTHUMG00000128943 UniprotKB:Q96HH9
NC_000005.10
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.942e-1 (AD)  1.361e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs4388209chr5:126422681 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRAMD2B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRAMD2B mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 affects the expression of GRAMD2B protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of GRAMD2B gene27153756
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of GRAMD2B mRNA24449571
C006632arsenic trioxidearsenic trioxide results in increased expression of GRAMD2B mRNA15070760
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of GRAMD2B mRNA"19150397
D004958EstradiolEstradiol results in decreased expression of GRAMD2B mRNA20106945
C039671ciglitazone[ciglitazone binds to PPARG protein alternative form] which results in increased expression of GRAMD2B mRNA16197558
D003300Copper[Disulfiram binds to Copper] which results in increased expression of GRAMD2B mRNA24690739
D016572CyclosporineCyclosporine results in decreased expression of GRAMD2B mRNA20106945
D004221Disulfiram[Disulfiram binds to Copper] which results in increased expression of GRAMD2B mRNA24690739
C118739entinostatentinostat results in increased expression of GRAMD2B mRNA27188386
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GRAMD2B mRNA22079256
D005557FormaldehydeFormaldehyde results in decreased expression of GRAMD2B mRNA20655997
D017313FenretinideFenretinide results in decreased expression of GRAMD2B mRNA28973697
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of GRAMD2B mRNA26752646
D018021Lithium ChlorideLithium Chloride results in increased expression of GRAMD2B mRNA23527032
C406082monomethylarsonous acidmonomethylarsonous acid results in increased expression of GRAMD2B protein24625837
C016340o,p'-DDT"o,p'-DDT results in decreased expression of GRAMD2B mRNA"18204070
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRAMD2B mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of GRAMD2B mRNA26272509
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GRAMD2B mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of GRAMD2B mRNA22079256
C005556propionaldehydepropionaldehyde results in increased expression of GRAMD2B mRNA26079696
D018038Sodium SeleniteSodium Selenite results in decreased expression of GRAMD2B mRNA18175754
C012589trichostatin Atrichostatin A results in increased expression of GRAMD2B mRNA24935251
D014635Valproic AcidValproic Acid results in increased expression of GRAMD2B mRNA23179753|2438349
D014750VincristineVincristine results in increased expression of GRAMD2B mRNA23649840
C111237vorinostatvorinostat results in increased expression of GRAMD2B mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI25416956  25910212  26871637  27107014  
GO:0042802identical protein binding-IPI25416956  
GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO:0005881cytoplasmic microtubule-IDA23264731  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal